ArticlePediatric transplantation2015
The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant.
Article in Pediatric transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Novel insights from a large cohort: Elucidating incidence, risk factors, treatment, and prognostic predictors in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.Journal of translational internal medicine · 2026Article
- Fostamatinib Dual Immunomodulation in Post-Haploidentical HSCT Autoimmune Cytopenia and Autoimmune Hepatitis: A Case Report and Review of Literature.Journal of clinical immunology · 2026Review
- A stepwise institutional approach to refractory autoimmune cytopenia after allogeneic stem cell transplantation in children: a retrospective case series.Frontiers in immunology · 2026Article
- A case report on the treatment of autoimmune hemolytic anemia after CBT by daratumumab in a mucopolysaccharidosis type III patient.Medicine · 2025Article
- Autoimmune Hemolytic Anemia: A Challenging Complication of Allogeneic Hematopoietic Stem Cell Transplant.Cureus · 2024Article
- Autoimmune cytopenias following pediatric hematopoietic cell transplant.Bone marrow transplantation · 2024Article
- Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review.Clinical hematology international · 2024Review
- Review
- Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.Blood advances · 2022Review
- Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant.Pediatric blood & cancer · 2022Article
- Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.Bone marrow transplantation · 2021Review
- Outcome of Non-hematological Autoimmunity After Hematopoietic Cell Transplantation in Children with Primary Immunodeficiency.Journal of clinical immunology · 2021Article
- Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT).Bone marrow transplantation · 2020Article
- Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2020Review
- Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.Blood advances · 2018Article
- Immune-mediated cytopenia in pediatric primary immune deficiency patients following HSCT.Bone marrow transplantation · 2017Article
- Blood Group Discrepancy-First Sign of Autoimmune Hemolytic Anemia after Hematopoietic Stem Cell Transplantation in a Child.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The reported incidence of post-allogeneic HSCT AIHA was between 4.4% and 6% following a single transplant. Cord blood transplantation, T-cell depletion, and chronic GvHD are significantly associated with post-transplant AIHA. During an 11-yr period, data for 500 pediatric HSCT recipients were eligible for evaluation of the incidence of AIHA post-first and post-second transplants. Demographic, transplant, and post-transplant-related variables were analyzed. Twelve of 500 (2.4%) recipients at a median of 273 days and seven of 72 (9.7%) recipients at a median of 157 days developed AIHA post-first and post-second HSCT, respectively. Post-first HSCT, none of the MRD recipients developed AIHA (0/175 MRD vs. 12/325 other donors, p = 0.04). Four of 12 required a second HSCT to control the AIHA. After the second HSCT, MUD was significantly associated with the development of AIHA. No other variables were associated with the post-second transplant AIHA. The incidence of AIHA post-first and post-second HSCT was less than the reported. The increased incidence of AIHA among recipients of second HSCT is most likely due to the profound immune dysregulation. A much larger, prospective study would be needed to evaluate the incidence, complications, and management of post-transplant AIHA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.